1
|
Ghasemi-Gujani M, Savabi-Esfahani M, Noroozi M, Satari M. Development of mobile application for cervical cancer screening in women: Protocol of a multi-phase study. JOURNAL OF EDUCATION AND HEALTH PROMOTION 2024; 13:5. [PMID: 38525208 PMCID: PMC10959268 DOI: 10.4103/jehp.jehp_1603_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Accepted: 01/30/2023] [Indexed: 03/26/2024]
Abstract
BACKGROUND Cervical cancer is one of the most common cancers in women. It is considered preventable due to the possibility of screening. The common barriers to cervical cancer screening include lack of knowledge, lack of time, and wrong beliefs. The use of e-Health technologies is one of the approaches for health promotion. The present study is aimed to the development of a mobile application for cervical cancer screening in women. MATERIALS AND METHOD This is a multi-phase study. In the first step, a literature review will be conducted to examine factors related to cervical cancer screening and existing applications related to cervical cancer and its screening. Then, in the second step, a cross-sectional study will be conducted to investigate the factors related to cervical cancer screening in 246 women referred to comprehensive health centers and women's clinics in teaching hospitals in Isfahan, Iran. The comprehensive health centers and women's clinics in teaching hospitals will be randomly selected using a lottery method. Using convenience sampling, women who meet the inclusion criteria will be included in the study, provided they provide informed consent. The data will be collected using a questionnaire, and then the descriptive and inferential statistical tests and SPSS18 software will be used to analyze the data. In the third step, specialists (gynecologists, reproductive health specialists, and midwives) will prioritize the application content by filling out a questionnaire. Then, the research team will compile the application content draft, and this draft will be reviewed and approved by experts on the expert panel. The prototype of the application will be prepared, and experts will evaluate it in the fifth step. DISCUSSION The results of this study will result in the development of applications for cervical cancer screening. The use of mobile applications can be useful in lifting some of the barriers to screening. Therefore, developing such applications may help improve cervical cancer screening.
Collapse
Affiliation(s)
- Marzieh Ghasemi-Gujani
- PhD Candidate, Department of Midwifery and Reproductive Health, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mitra Savabi-Esfahani
- Department of Midwifery and Reproductive Health, Nursing and Midwifery Care Research Center, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mahnaz Noroozi
- Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mohammad Satari
- Department Health Information Technology, Health Information Technology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| |
Collapse
|
2
|
AziziKia H, Didar H, Teymourzadeh A, Nakhostin-Ansari A, Jafari Doudaran P, Ferasatifar B, Hoveidaei A, Roshandel G. Uterine and Cervical Cancer in Iran: An epidemiologic analysis of the Iranian National Population-Based Cancer Registry. ARCHIVES OF IRANIAN MEDICINE 2023; 26:1-7. [PMID: 37543915 PMCID: PMC10685806 DOI: 10.34172/aim.2023.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Accepted: 08/27/2022] [Indexed: 08/08/2023]
Abstract
BACKGROUND Gynecologic cancers, including neoplasms of the cervix and uterine, are the fourth most common malignancies, causing 3.46% of deaths in women aged 15 to 59. OBJECTIVES We aimed to report the Iranian National Population-based Cancer Registry (INPCR) results for Cervical and Uterine cancers in 2017. METHODS The total population of Iran in 2017 was 80881792. INPCR collected data on cervical and uterine cancer incidence from 31 provinces of Iran. In this project, we retrospectively examined all the country's regions in terms of screening for the existence of these two cancers. The registry data bank in Iran was used. RESULTS Overall, 3481 new cervical and uterine cancer cases were registered in INPCR, including 842 cases of cervical cancer (with a crude rate of 1.04) and 2639 cases of uterine cancer (with a crude rate of 3.26). The average age-standardized incidence rate (ASR) was 0.99 for cervical cancer and 3.29 for uterine cancer. Out of 3481 new cervical and uterine cancer cases, 2887 were registered with pathological findings and 594 without pathological confirmation. In cervical cancers, the highest rate was related to squamous cell carcinoma, with 486 cases (57.72%). CONCLUSION Our results showed that Iran is a low-risk area for the incidence of cervical and uterine cancers. In this study, the highest rate of cervical cancer was related to squamous cell carcinoma, confirming previous reports. However, this rate was lower than previous studies and suggested an increase in other types of cervical cancer in Iran.
Collapse
Affiliation(s)
- Hani AziziKia
- Student Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Hamidreza Didar
- Preventative Gynecology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Azin Teymourzadeh
- Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
| | - Amin Nakhostin-Ansari
- Sports Medicine Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
| | | | - Bahareh Ferasatifar
- Department of Chemistry, Iran University of Science and Technology, Tehran, Iran
| | - Armin Hoveidaei
- BSc in Radiotherapy Technology, Student Research Committee, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Gholamreza Roshandel
- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
| |
Collapse
|
3
|
Nemati S, Saeedi E, Roshandel G, Nahvijou A, Badakhshan A, Akbari M, Sedaghat SM, Hasanpour-Heidari S, Hosseinpour R, Salamat F, Lotfi F, Khosravi A, Soerjomataram I, Bray F, Zendehdel K. Population-based cancer survival in the Golestan province in the northeastern part of Iran 2007-2012. Cancer Epidemiol 2022; 77:102089. [PMID: 35042146 DOI: 10.1016/j.canep.2021.102089] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Revised: 12/15/2021] [Accepted: 12/17/2021] [Indexed: 12/23/2022]
Abstract
OBJECTIVE We studied 5-year relative survival (RS) for 14 leading cancer sites in the population-based cancer registry (PBCR) of Golestan province in the northeastern part of Iran. METHODOLOGY We followed patients diagnosed in 2007-2012 through data linkage with different databases, including the national causes of death registry and vital statistics office. We also followed the remaining patients through active contact. We used relative survival (RS) analysis to estimate 5-year age-standardized net survival for each cancer site. Multiple Imputation (MI) method was performed to obtain vital status for loss to follow-up (LTFU) cases. RESULTS We followed 6910 cancer patients from Golestan PBCR. However, 2162 patients were loss to follow-up. We found a higher RS in women (29.5%, 95% CI, 27.5, 31.7) than men (21.0%, 95% CI, 19.5, 22.5). The highest RS was observed for breast cancer in women (RS=49.8%, 95% CI, 42.2, 56.9) and colon cancer in men (RS=37.9%, 95% CI, 31.2, 44.6). Pancreatic cancer had the lowest RS both in men (RS= 8.7%, 95% CI, 4.1, 13.5) and women (RS= 7.9%, 95% CI, 5.0, 10.8) CONCLUSION: Although the 5-year cancer survival rates were relatively low in the Golestan province, there were distinct variations by cancer site. Further studies are required to evaluate the survival trends in Golestan province over time and compare them with the rates in the neighboring provinces and other countries in the region.
Collapse
Affiliation(s)
- Saeed Nemati
- Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Elnaz Saeedi
- Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Gholamreza Roshandel
- Golestan Research Centre of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
| | - Azin Nahvijou
- Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Abbas Badakhshan
- Department of Public Health, Golestan University of Medical Sciences, Gorgan, Iran
| | - Mahnaz Akbari
- Deputy of Treatment, Golestan University of Medical Sciences, Gorgan, Iran
| | - Seyed Mehdi Sedaghat
- Department of Public Health, Golestan University of Medical Sciences, Gorgan, Iran
| | - Susan Hasanpour-Heidari
- Golestan Research Centre of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
| | - Reza Hosseinpour
- Golestan Research Centre of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
| | - Faezeh Salamat
- Department of Public Health, Golestan University of Medical Sciences, Gorgan, Iran
| | - Fereshteh Lotfi
- Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
| | | | | | - Freddie Bray
- Cancer Surveillance Branch, International Agency for Research on Cancer, France
| | - Kazem Zendehdel
- Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
4
|
Roshandel G, Ferlay J, Ghanbari-Motlagh A, Partovipour E, Salavati F, Aryan K, Mohammadi G, Khoshaabi M, Sadjadi A, Davanlou M, Asgari F, Abadi H, Aghaei A, Ahmadi-Tabatabaei SV, Alizadeh-Barzian K, Asgari A, Asgari N, Azami S, Cheraghi M, Enferadi F, Eslami-Nasab M, Fakhery J, Farahani M, Farrokhzad S, Fateh M, Ghasemi A, Ghasemi-Kebria F, Gholami H, Golpazir A, Hasanpour-Heidari S, Hazar N, Hoseini-Hoshyar H, Izadi M, Jahantigh M, Jalilvand A, Jazayeri SM, Kazemzadeh Y, Khajavi M, Khalednejad M, Khanloghi M, Kooshki M, Madani A, Mirheidari M, Mohammadifar H, Moinfar Z, Mojtahedzadeh Y, Morsali A, Motidost-Komleh R, Mousavi T, Narooei M, Nasiri M, Niksiar S, Pabaghi M, Pirnejad H, Pournajaf A, Pourshahi G, Rahnama A, Rashidpoor B, Ravankhah Z, Rezaei K, Rezaianzadeh A, Sadeghi G, Salehifar M, Shahdadi A, Shahi M, Sharifi-Moghaddam F, Sherafati R, Soleimani A, Soltany-Hojatabad M, Somi MH, Yadolahi S, Yaghoubi-Ashrafi M, Zareiyan A, Poustchi H, Zendehdel K, Ostovar A, Janbabaei G, Raeisi A, Weiderpass E, Malekzadeh R, Bray F. Cancer in Iran 2008 to 2025: Recent incidence trends and short-term predictions of the future burden. Int J Cancer 2021; 149:594-605. [PMID: 33884608 DOI: 10.1002/ijc.33574] [Citation(s) in RCA: 60] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Revised: 02/25/2021] [Accepted: 03/12/2021] [Indexed: 12/21/2022]
Abstract
Policymakers require estimates of the future number of cancer patients in order to allocate finite resources to cancer prevention, treatment and palliative care. We examine recent cancer incidence trends in Iran and present predicted incidence rates and new cases for the entire country for the year 2025. We developed a method for approximating population-based incidence from the pathology-based data series available nationally for the years 2008 to 2013, and augmented this with data from the Iranian National Population-based Cancer Registry (INPCR) for the years 2014 to 2016. We fitted time-linear age-period models to the recent incidence trends to quantify the future cancer incidence burden to the year 2025, delineating the contribution of changes due to risk and those due to demographic change. The number of new cancer cases is predicted to increase in Iran from 112 000 recorded cases in 2016 to an estimated 160 000 in 2025, a 42.6% increase, of which 13.9% and 28.7% were attributed to changes in risk and population structure, respectively. In terms of specific cancers, the greatest increases in cases are predicted for thyroid (113.8%), prostate (66.7%), female breast (63.0%) and colorectal cancer (54.1%). Breast, colorectal and stomach cancers were the most common cancers in Iran in 2016 and are predicted to remain the leading cancers nationally in 2025. The increasing trends in incidence of most common cancers in Iran reinforce the need for the tailored design and implementation of effective national cancer control programs across the country.
Collapse
Affiliation(s)
- Gholamreza Roshandel
- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
- Iranian National Population-Based Cancer Registry Secretariat, Cancer Office, Deputy of Health, Ministry of Health, Tehran, Iran
| | - Jacques Ferlay
- Cancer Surveillance Branch, International Agency for Research on Cancer (IARC), World Health Organization (WHO), Lyon, France
| | - Ali Ghanbari-Motlagh
- National Cancer Management Committee, Deputy of Health, Ministry of Health, Tehran, Iran
| | - Elham Partovipour
- Iranian National Population-Based Cancer Registry Secretariat, Cancer Office, Deputy of Health, Ministry of Health, Tehran, Iran
| | - Fereshteh Salavati
- Iranian National Population-Based Cancer Registry Secretariat, Cancer Office, Deputy of Health, Ministry of Health, Tehran, Iran
| | - Kimia Aryan
- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
| | - Gohar Mohammadi
- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mostafa Khoshaabi
- Iranian National Population-Based Cancer Registry Secretariat, Cancer Office, Deputy of Health, Ministry of Health, Tehran, Iran
| | - Alireza Sadjadi
- Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
| | | | - Fereshteh Asgari
- Iranian National Population-Based Cancer Registry Secretariat, Cancer Office, Deputy of Health, Ministry of Health, Tehran, Iran
| | - Hakimeh Abadi
- Booshehr Cancer Registry, Booshehr University of Medical Sciences, Booshehr, Iran
| | - Abbas Aghaei
- Cancer and Immunology Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran
| | | | | | - Abbasali Asgari
- Shahrekoord Cancer Registry, Shahrekoord University of Medical Sciences, Shahrekoord, Iran
| | - Noorali Asgari
- Zabol Cancer Registry, Zabol University of Medical Sciences, Zabol, Iran
| | - Soheyla Azami
- Saveh Cancer Registry, Saveh Faculty of Medical Sciences, Saveh, Iran
| | - Maria Cheraghi
- Cancer Research Center, Cancer Registry Section, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
| | - Floria Enferadi
- Khorasan-North Cancer Registry, Khorasan-North University of Medical Sciences, Bojnord, Iran
| | | | - Jila Fakhery
- Khoy Cancer Registry, Khoy Faculty of Medical Sciences, Khoy, Iran
| | - Mohsen Farahani
- Arak Cancer Registry, Arak University of Medical Sciences, Arak, Iran
| | - Solmaz Farrokhzad
- Qazvin Cancer Registry, Qazvin University of Medical Sciences, Qazvin, Iran
| | - Mansooreh Fateh
- Center for Health Related Social and Behavioral Sciences Research, Shahroud University of Medical Sciences, Shahrood, Iran
| | - Ali Ghasemi
- Birjand Cancer Registry, Birjand University of Medical Sciences, Birjand, Iran
| | - Fatemeh Ghasemi-Kebria
- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
| | - Hajar Gholami
- Ardabil Cancer Registry, Ardabil University of Medical Sciences, Ardabil, Iran
| | - Arash Golpazir
- Kermanshah Cancer Registry, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Susan Hasanpour-Heidari
- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
| | - Narjes Hazar
- Department of Community Medicine, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
| | | | - Mohsen Izadi
- Gerash Cancer Registry, Gerash Faculty of Medical Sciences, Gerash, Iran
| | - Mahdi Jahantigh
- Zahedan Cancer Registry, Zahedan University of Medical Sciences, Zahedan, Iran
| | - Ahmad Jalilvand
- Zanjan Cancer Registry, Zanjan University of Medical Sciences, Zanjan, Iran
| | | | - Yasan Kazemzadeh
- Khomein Cancer Registry, Khomein Faculty of Medical Sciences, Khomein, Iran
| | - Maryam Khajavi
- Dezful Cancer Registry, Dezful University of Medical Sciences, Dezful, Iran
| | - Maryam Khalednejad
- Alborz Cancer Registry, Alborz University of Medical Sciences, Karaj, Iran
| | - Marziyeh Khanloghi
- Nishabour Cancer Registry, Nishabour Faculty of Medical Sciences, Nishabour, Iran
| | - Maryam Kooshki
- Lorestan Cancer Registry, Lorestan University of Medical Sciences, Khoramabad, Iran
| | - Amineh Madani
- Abadan Cancer Registry, Abadan Faculty of Medical Sciences, Abadan, Iran
| | - Mahdi Mirheidari
- Qom Cancer Registry, Qom University of Medical Sciences, Qom, Iran
| | | | - Zeinab Moinfar
- Tehran Cancer Registry, Tehran University of Medical Sciences, Tehran, Iran
| | | | - Ali Morsali
- Asadabad Cancer Registry, Asadabad Faculty of Medical Sciences, Asadabad, Iran
| | | | - Tahereh Mousavi
- Babol Cancer Registry, Babol University of Medical Sciences, Babol, Iran
| | - Maboobeh Narooei
- Iranshahr Cancer Registry, Iranshahr University of Medical Sciences, Iranshahr, Iran
| | - Mohammad Nasiri
- Shooshtar Cancer Registry, Shooshtar Faculty of Medical Sciences, Shooshtar, Iran
| | - Sharareh Niksiar
- Hamedan Cancer Registry, Hamedan University of Medical Sciences, Hamedan, Iran
| | - Mehdi Pabaghi
- Larestan Cancer Registry, Larestan Faculty of Medical Sciences, Lar, Iran
| | - Habibollah Pirnejad
- Patient Safety Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran
| | - Azadeh Pournajaf
- Ilam Cancer Registry, Ilam University of Medical Sciences, Ilam, Iran
| | - Gita Pourshahi
- Torbatejam Cancer Registry, Torbatejam Faculty of Medical Sciences, Torbatejam, Iran
| | - Amir Rahnama
- Rafsanjan Cancer Registry, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
| | - Bahman Rashidpoor
- Yasoj Cancer Registry, Yasoj University of Medical Sciences, Yasoj, Iran
| | - Zahra Ravankhah
- Esfahan Cancer Registry, Esfahan University of Medical Sciences, Esfahan, Iran
| | - Khadijeh Rezaei
- Mashhad Cancer Registry, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Abbas Rezaianzadeh
- Shiraz Cancer Registry, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Gholamreza Sadeghi
- Guilan Cancer Registry, Guilan University of Medical Sciences, Rasht, Iran
| | - Mohammad Salehifar
- Torbateheidarieh Cancer Registry, Torbateheidarieh University of Medical Sciences, Torbatheidarieh, Iran
| | - Athareh Shahdadi
- Jiroft Cancer Registry, Jiroft University of Medical Sciences, Jiroft, Iran
| | - Mehraban Shahi
- Hormozgan Cancer Registry, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
| | | | - Roya Sherafati
- Sarab Cancer Registry, Sarab Faculty of Medical Sciences, Sarab, Iran
| | - Ali Soleimani
- Maragheh Cancer Registry, Maragheh Faculty of Medical Sciences, Maragheh, Iran
| | | | - Mohammad-Hossein Somi
- Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Sohrab Yadolahi
- Semnan Cancer Registry, Semnan University of Medical Sciences, Semnan, Iran
| | | | - Aliakbar Zareiyan
- Jahrom Cancer Registry, Jahrom University of Medical Sciences, Jahrom, Iran
| | - Hossein Poustchi
- Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Kazem Zendehdel
- Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran
| | - Afshin Ostovar
- Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
| | | | - Alireza Raeisi
- Deputy Minister of Health, Ministry of Health, Tehran, Iran
| | - Elisabete Weiderpass
- Office of the Director, International Agency for Research on Cancer (IARC), Lyon, France
| | - Reza Malekzadeh
- Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Freddie Bray
- Cancer Surveillance Branch, International Agency for Research on Cancer (IARC), World Health Organization (WHO), Lyon, France
| |
Collapse
|
5
|
Farahmand Z, Soleimanjahi H, Garshasbi M, Hasanzadeh M, Zafari E. Distribution of the most common types of HPV in Iranian women with and without cervical cancer. Women Health 2020; 61:73-82. [PMID: 32957835 DOI: 10.1080/03630242.2020.1822490] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Cervical cancer is an important cause of death in women worldwide. About 99.7% of all cervical cancers have been related to human papillomavirus, especially types 16 and 18. Types 6 and 11 cause genital warts. We aimed to determine the prevalence of common HPV genotypes among women in the general population and women with cervical cancer. A total of 571 healthy women cytology specimens and 113 tissue samples of cervical cancer were investigated using HPV type-specific primers. HPV DNA was detected in 24% of healthy women: 3.3% were positive for high-risk HPV and 11.6% for low-risk HPV. HPV6 (9.3%) had the highest prevalence followed by HPV11 (2.3%), HPV16 (1.8%), HPV18 (1.2%), and 9.1% of samples were positive for unknown types. Among cervical cancer samples, HPV DNA was found in 78.8% including 43.4% HPV16, 8% HPV18, and 27.4% an unknown HPV type. HPV6 and HPV11 were not detected in any cervical cancer cases and 21.2% were negative for HPV. We found no association between HPV-16/18 and age in cervical cancer. The prevalence of HPV infection is relatively high in Iran without vaccination backgrounds. HPV DNA screening and vaccination programs can prevent cervical cancer and health problems caused by genital warts.
Collapse
Affiliation(s)
- Zohreh Farahmand
- Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University , Tehran, Iran
| | - Hoorieh Soleimanjahi
- Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University , Tehran, Iran
| | - Masoud Garshasbi
- Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University , Tehran, Iran
| | - Malihe Hasanzadeh
- Department of Gynecology Oncology, Woman Health Research Center, Faculty of Medicine, Mashhad University of Medical Sciences , Mashhad, Iran
| | - Ehsan Zafari
- Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University , Tehran, Iran
| |
Collapse
|
6
|
Samiee Rad F, Ghaebi M, Zarabadipour S, Bajelan A, Pashazade F, Kalhor M, Barikani A. Comparison of Diagnostic Methods in Detection of Squamous Cell Abnormalities in Iranian Women with Abnormal Pap's Smear Test and Associated Demographic and Issues. IRANIAN JOURNAL OF PATHOLOGY 2020; 15:106-116. [PMID: 32215026 DOI: 10.30699/ijp.2020.114626.2248] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Accepted: 02/15/2020] [Indexed: 01/24/2023]
Abstract
Background & Objective Premalignant lesions of cervix have increased dramatically in recent years. Early diagnosis and management of abnormalities have an effective role in preventing the invasion of the disease and also in timely treatment. This study aimed to compare diagnostic methods in the detection of squamous cell abnormalities with abnormal Pap smear test. Methods This cross-sectional study was performed on 1000 women with abnormal Pap smears in 2007-2018. Sampling was performed with simple method. All samples were subjected to an immediate assessment of colposcopy and histopathology if suspected. The checklist included demographic information as well as symptoms, cytopathology, colposcopy and histopathology findings. Data analysis was performed using descriptive and statistical analysis (P<0.05). Results A significant relationship between histopathology and Pap smear findings was found (P=0.009), also there was a significant correlation between histopathology and colposcopy findings (P=0.001). However, there was no significant relationship between clinical symptoms and histopathology findings (p=0.8). Sensitivity , specificity , positive and negative predictive value of Pap smear were 43%, 65.9%, 75.4%, 32.2% and of colposcopy were 74.7%, 39.5%, 75%, 39.1%, and of clinical symptoms were 72.6%, 28.1%, 71.1%, 29.7%, respectively. Conclusion Pap smear findings have the appropriate diagnostic accuracy in comparison with colposcopy and histopathology findings for screening and diagnosis of squamous intra-epithelial lesions. Also, there was higher sensitivity of colposcopy compared with Pap smear to detect cervical lesions. Therefore, it is advisable to use these methods simultaneously.
Collapse
Affiliation(s)
- Fatemeh Samiee Rad
- Department of Pathology, Metabolic Disease Research Center, Qazvin University of Medical Sciences, Qazvin, Iran
| | - Mahdi Ghaebi
- General Physician, Qazvin University of Medical Sciences, Qazvin, Iran
| | | | | | | | - Mehri Kalhor
- Department of Reproductive Health, Tarbiat Modarres University, Tehran, Iran
| | - Amane Barikani
- Department of Epidemiology, Qazvin University of Medical Sciences, Qazvin, Iran
| |
Collapse
|
7
|
Vahedpoor Z, Behrashi M, Khamehchian T, Abedzadeh-Kalahroudi M, Moravveji A, Mohmadi-Kartalayi M. Comparison of the diagnostic value of the visual inspection with acetic acid (VIA) and Pap smear in cervical cancer screening. Taiwan J Obstet Gynecol 2019; 58:345-348. [DOI: 10.1016/j.tjog.2019.03.010] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/20/2019] [Indexed: 10/26/2022] Open
|
8
|
Momenimovahed Z, Salehiniya H. Cervical cancer in Iran: integrative insights of epidemiological analysis. Biomedicine (Taipei) 2018; 8:18. [PMID: 30141405 PMCID: PMC6108227 DOI: 10.1051/bmdcn/2018080318] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Accepted: 03/19/2018] [Indexed: 01/09/2023] Open
Abstract
Background: Cervical cancer is a common cancer among women around the world. Due to the geographical differences in incidence, mortality and risk factors of cervical cancer, it is necessary to conduct different studies in different countries. This review study is aimed to investigate the most important aspects of cervical cancer in Iran. Methods: Reviewing papers without time limitation was conducted with the keywords cervical cancer, Cervix uteri cancer and Iran in their title or abstract. The databases of Medline, IranMedex, SID, ScienceDirect, Embase, Google Scholar, Web of Science, and Scopus were searched. The title and abstract of the papers were reviewed, in all, 51 full papers were reviewed. Results: Based on published studies, the incidence of cervical cancer varies between different areas of Iran. The findings of this study demonstrated that there is a relationship between marital status, marriage age, and age of first pregnancy, smoking, and consumption of oral contraceptive pills, multiple sexual partners, family history, multiparty, and cervical cancer. Conclusion: The results of this review showed that the incidence of cervical cancer in Iran is low; however, the risk factors associated with this cancer are not few, which could lead to the increase in the incidence of cervical cancer in the future.
Collapse
Affiliation(s)
| | - Hamid Salehiniya
- Zabol University of Medical Sciences, Zabol, Iran - Department of Epidemiology and Biostatistics, Tehran University of medical sciences, Tehran, Iran
| |
Collapse
|
9
|
Roshandel G, Semnani S, Fazel A, Honarvar M, Taziki M, Sedaghat S, Abdolahi N, Ashaari M, Poorabbasi M, Hasanpour S, Hosseini S, Mansuri S, Jahangirrad A, Besharat S, Moghaddami A, Mirkarimi H, Salamat F, Ghasemi-Kebria F, Jafari N, Shokoohifar N, Gholami M, Sadjadi A, Poustchi H, Bray F, Malekzadeh R. Building cancer registries in a lower resource setting: The 10-year experience of Golestan, Northern Iran. Cancer Epidemiol 2018; 52:128-133. [PMID: 29306787 DOI: 10.1016/j.canep.2017.12.014] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2017] [Revised: 12/11/2017] [Accepted: 12/19/2017] [Indexed: 01/04/2023]
Abstract
INTRODUCTION The Golestan population-based cancer registry (GPCR) was established in Golestan province, Northern Iran, within the Asian belt with predominance of upper-gastrointestinal cancers. We aimed to present the experiences of the registry in a resource-limited setting over the 10 years since its inception (2004-2013). METHODS The GPCR was established as a research project to enable sustainable funding. A clear plan was developed for use of the GPCR data. New primary cancers were registered based on international standards, indices of data quality were routinely assessed and age-standardized incidence rates (ASR) per 100,000 person-years calculated using IARC's CanReg-5 software. RESULTS Overall, 19807 new cancer cases were registered during the study period, an average of 1981 cases per annum, with overall ASR of 175.0 and 142.4 in males and females, respectively. The GPCR data suggested gastrointestinal and breast cancers as the most common malignancies in Golestan province. We observed increasing incidence rates of breast and colorectal cancers but declining trends of esophageal cancer. Overall, indices of data quality were within acceptable ranges. CONCLUSIONS The GPCR data have been included in IARC's Cancer Incidence in Five Continents series, were used in 21 research projects, and published as 30 research papers. The key ingredients for the successful establishment and maintenance of the GPCR included sustainable sources of funding, a clear action plan for the use of data as well as stakeholder cooperation across all areas of the registration. The GPCR may be considered as a model for planning population-based cancer registries in lesser-resourced settings.
Collapse
Affiliation(s)
- Gholamreza Roshandel
- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
| | - Shahryar Semnani
- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
| | - Abdolreza Fazel
- Hyrcania Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran
| | | | - MohammadHossein Taziki
- Hyrcania Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran; Deputy of Research and Technology, Golestan University of Medical Sciences, Gorgan, Iran
| | - SeyedMehdi Sedaghat
- Deputy of Public Health, Golestan University of Medical Sciences, Gorgan, Iran
| | - Nafiseh Abdolahi
- Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran
| | - Mohammad Ashaari
- Department of Pathology, Sayyad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran
| | - Mohammad Poorabbasi
- Death Registry Unit, Deputy of Public Health, Golestan University of Medical Sciences, Gorgan, Iran
| | - Susan Hasanpour
- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
| | | | - SeyedMohsen Mansuri
- Statistics and Information Technology Office, Golestan University of Medical Sciences, Gorgan, Iran
| | | | - Sima Besharat
- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
| | - Abbas Moghaddami
- Deputy of Public Health, Golestan University of Medical Sciences, Gorgan, Iran
| | - Honeyehsadat Mirkarimi
- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
| | - Faezeh Salamat
- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
| | - Fatemeh Ghasemi-Kebria
- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
| | - Nastaran Jafari
- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
| | - Nesa Shokoohifar
- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
| | - Masoomeh Gholami
- Death Registry Unit, Deputy of Public Health, Golestan University of Medical Sciences, Gorgan, Iran
| | - Alireza Sadjadi
- Digestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Hossein Poustchi
- Digestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Freddie Bray
- Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France
| | - Reza Malekzadeh
- Digestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
10
|
Regional Differences in Cancer Incidence Trend in Tehran, Iran: A Contextual Study on the Effect of Socioeconomic Status at Regional Level. INTERNATIONAL JOURNAL OF CANCER MANAGEMENT 2018. [DOI: 10.5812/ijcm.6641] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
11
|
Rezaianzadeh A, Dehghani SL, Mousavi M, Rezaeianzadeh R. The Incidence of Uterus Cancer in Iran: A Systematic Review. WOMEN’S HEALTH BULLETIN 2016. [DOI: 10.17795/whb-42917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
12
|
Roder D, Karapetis CS, Wattchow D, Moore J, Singhal N, Joshi R, Keefe D, Fusco K, Buranyi-Trevarton D, Sharplin G, Price TJ. Metastatic Colorectal Cancer Treatment and Survival: the Experience of Major Public Hospitals in South Australia Over Three Decades. Asian Pac J Cancer Prev 2016; 16:5923-31. [PMID: 26320474 DOI: 10.7314/apjcp.2015.16.14.5923] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Registry data from four major public hospitals indicate trends over three decades from 1980 to 2010 in treatment and survival from colorectal cancer with distant metastases at diagnosis (TNM stage IV). MATERIALS AND METHODS Kaplan-Meier product-limit estimates and Cox proportional hazards models for investigating disease-specific survival and multiple logistic regression analyses for indicating first-round treatment trends. RESULTS Two-year survivals increased from 10% for 1980-84 to 35% for 2005-10 diagnoses. Corresponding increases in five-year survivals were from 3% to 16%. Time-to-event risk of colorectal cancer death approximately halved (hazards ratio: 0.48 (0.40, 0.59) after adjusting for demographic factors, tumour differentiation, and primary sub-site. Survivals were not found to differ by place of residence, suggesting reasonable equity in service provision. About 74% of cases were treated surgically and this proportion increased over time. Proportions having systemic therapy and/or radiotherapy increased from 12% in 1980-84 to 61% for 2005-10. Radiotherapy was more common for rectal than colonic cases (39% vs 7% in 2005-10). Of the cases diagnosed in 2005-10 when less than 70 years of age, the percentage having radiotherapy and/or systemic therapy was 79% for colorectal, 74% for colon and 86% for rectum (and RS)) cancers. Corresponding proportions having: systemic therapies were 75%, 71% and 81% respectively; radiotherapy were 24%, 10% and 46% respectively; and surgery were 75%, 78% and 71% respectively. Based on survey data on uptake of offered therapies, it is likely that of these younger cases, 85% would have been offered systemic treatment and among rectum (and RS) cases, about 63% would have been offered radiotherapy. CONCLUSIONS Pronounced increases in survivals from metastatic colorectal cancer have occurred, in keeping with improved systemic therapies and surgical interventions. Use of radiotherapy and/or systemic therapy has increased markedly and patterns of change accord with clinical guideline recommendations.
Collapse
Affiliation(s)
- David Roder
- Centre for Population Health Research, University of South Australia, South Australia E-mail :
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Roder D, Karapetis CS, Wattchow D, Moore J, Singhal N, Joshi R, Keefe D, Fusco K, Powell K, Eckert M, Price TJ. Colorectal cancer treatment and survival: the experience of major public hospitals in south Australia over three decades. Asian Pac J Cancer Prev 2016; 16:2431-40. [PMID: 25824777 DOI: 10.7314/apjcp.2015.16.6.2431] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Registry data from four major public hospitals indicate trends in clinical care and survival from colorectal cancer over three decades, from 1980 to 2010. MATERIALS AND METHODS Kaplan-Meier product- limit estimates and Cox proportional hazards models were used to investigate disease-specific survival and multiple logistic regression analyses to explore first-round treatment trends. RESULTS Five-year survivals increased from 48% for 1980-1986 to 63% for 2005-2010 diagnoses. Survival increases applied to each ACPS stage (Australian Clinico-Pathological Stage), and particularly stage C (an increase from 38% to 68%). Risk of death from colorectal cancer halved (hazards ratio: 0.50 (0.45, 0.56)) over the study period after adjusting for age, sex, stage, differentiation, primary sub-site, health administrative region, and measures of socioeconomic status and geographic remoteness. Decreases in stage were not observed. Survivals did not vary by sex or place of residence, suggesting reasonable equity in service access and outcomes. Of staged cases, 91% were treated surgically with lower surgical rates for older ages and more advanced stage. Proportions of surgical cases having adjuvant therapy during primary courses of treatment increased for all stages and were highest for stage C (an increase from 5% in 1980-1986 to 63% for 2005-2010). Radiotherapy was more common for rectal than colonic cases. Proportions of rectal cases receiving radiotherapy increased, particularly for stage C where the increase was from 8% in 1980-1986 to 60% in 2005-2010. The percentage of stage C colorectal cases less than 70 years of age having systemic therapy as part of their first treatment round increased from 3% in 1980-1986 to 81% by 1995-2010. Based on survey data on uptake of adjuvant therapy among those offered this care, it is likely that all these younger patients were offered systemic treatment. CONCLUSIONS We conclude that pronounced increases in survivals from colorectal cancer have occurred at major public hospitals in South Australia due to increases in stage-specific survivals. Use of adjuvant therapies has increased and the patterns of change accord with clinical guideline recommendations. Reasons for sub-optimal use of radiotherapy for rectal cases warrant further investigation, including the potential for limited rural access to impede uptake of treatments at metropolitan-based radiotherapy centres.
Collapse
Affiliation(s)
- David Roder
- School of Population Health, University of South Australia, Adelaide, South Australia E-mail :
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Rafiemanesh H, Rajaei-Behbahani N, Khani Y, Hosseini S, Pournamdar Z, Mohammadian-Hafshejani A, Soltani S, Hosseini SA, Khazaei S, Salehiniya H. Incidence Trend and Epidemiology of Common Cancers in the Center of Iran. Glob J Health Sci 2015; 8:146-55. [PMID: 26493417 PMCID: PMC4804019 DOI: 10.5539/gjhs.v8n3p146] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2015] [Accepted: 05/27/2015] [Indexed: 12/29/2022] Open
Abstract
Introduction: Cancer is a major public health problem in Iran and many other parts of the world. The cancer incidence is different in various countries and in country provinces. Geographical differences in the cancer incidence lead to be important to conduct an epidemiological study of the disease. This study aimed to investigate cancer epidemiology and trend in the province of Qom, located in center of Iran. Method: This is an analytical cross-sectional study carried out based on re-analysis cancer registry report and the disease management center of health ministry from 2004 to 2008 in the province of Qom. To describe incidence time trends, we carried out join point regression analysis using the software Join point Regression Program, Version 4.1.1.1. Results: There were 3,029 registered cases of cancer during 5 years studied. Sex ratio was 1.32 (male to female). Considering the frequency and mean standardized incidence, the most common cancer in women were breast, skin, colorectal, stomach, and esophagus, respectively while in men the most common cancers included skin, stomach, colorectal, bladder, and prostate, respectively. There was an increasing and significant trend, according to the annual percentage change (APC) equal to 8.08% (CI: 5.1-11.1) for all site cancer in women. Conclusion: The incidence trend of all cancers was increasing in this area. Hence, planning for identifying risk factors and performing programs for dealing with the disease are essential.
Collapse
|